Bioequivalence and Bioavailability Forum 00:16 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Bioanalysis discontinued subject [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2018-08-02 11:14  - Posting: # 19127
Views: 1,002

Hi Johanne,

first of all, from a data perspective I agree with what Helmut said.

However, I recall a case where the authority interpretation of a withdrawn consent was that if a trial subject withdraws her consent, then it implicitly also implies that she withdraws her permission for the CRO to touch the un-analysed samples she has given up until the time of consent retraction. This is of course a matter of interpretation, but actually it also makes sense to me.
When it comes to rights of trial subjects there is no reason to take any chances. In this regard we need to think about ICH E6 §2.3 - rights, safety and well-being before science. Other clauses are in play, too.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,931 posts in 4,039 threads, 1,285 registered users;
online 7 (0 registered, 7 guests [including 4 identified bots]).

A drug is not bad. A drug is a chemical compound.
The problem comes in when people who take drugs treat them
like a license to behave like an asshole.    Frank Zappa

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed